1. Ansseau M, Pitchot W, Hansenne M, Gonzalez Moreno A. Psychotic reactions to zolpidem. Lancet 1992; 339: 809. doi: 10.1016/0140-6736(92)91935-2
2.
Aragona M. Abuse, dependence, and epileptic seizures after zolpidem withdrawal: review and case report. Clin Neu ropharmacol 2000; 23: 281–283. doi: 10.1097/00002826- 20000900000008.
3.
Coleman DE, Ota K. Hallucinations with zolpidem and fluox etine in an impaired driver. J Forensic Sci 2004; 49: 392–393.
4.
Cubała WJ, Gabrielsson A. Sleep related amnestic behav iors due to zolpidem. Bull Clin Psychopharmacol 2014; 24: 188–194.
5.
Cubała WJ, Landowski J, Wichowicz HM. Zolpidem abuse, dependence and withdrawal syndrome: sex as susceptibility factor for adverse effects. Br J Clin Pharmacol 2008; 65:444– 445. doi: 10.1111/j.1365-2125.2007.03028.x.
6.
Cubała WJ, Landowski J. Seizure following sudden zolpidem withdrawal. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 539–540. doi: 10.1016/j.pnpbp.2006.07.009.
7.
Cubała WJ, Wichowicz HM. Dependence on zolpidem: is pharmacokinetics important?. Psychiatry Clin Neurosci 2008; 62: 127. doi: 10.1111/j.1440-1819.2007.01784.x.
8.
Daley C, McNiel DE, Binder RL. “I did what?” Zolpidem and the courts. J Am Acad Psychiatry Law 2011; 39: 535–542.
9.
Dolder CR, Nelson MH. Hypnosedative-induced complex behaviours: incidence, mechanisms and management. CNS Drugs 2008; 22: 1021–1036. doi: 10.2165/0023210200822120- 00005.
10.
Drover DR. Comparative pharmacokinetics and pharmaco dynamics of short-acting hypnosedatives: zaleplon, zolpi dem and zopiclone. Clin Pharmacokinet 2004; 43: 227–238. doi: 10.2165/00003088-200443040-00002.
11.
Elko CJ, Burgess JL, Robertson WO. Zolpidem-associated hal lucinations and serotonin reuptake inhibition: a possible interaction. J Toxicol Clin Toxicol 1998; 36: 195–203. doi: 10.3109/15563659809028939.
12.
FDA. (2007) FDA requests label change for all sleep disor der drug products. [online]. Available at: https://wayback. archiveit.org/7993/20170112032141/http://www.fda.gov/ NewsEvents/Ne wsroom/PressAnnouncements/2007/ ucm108868.htm (last accessed on 14.02.2020).
13.
FDA. (2013) FDA Drug Safety Communication: Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist) [online]. Available at: https://wayback.archive it.org/7993/20170404172106/https://www.fda.gov/Drugs/ DrugSafety/ucm334033.htm (last accessed on 3.01.2020).
14.
Ganzoni E, Santoni JP, Chevillard V, Sébille M, Mathy B. Zolpidem in insomnia: a 3-year post-marketing surveil lance study in Switzerland. J Int Med Res 1995; 23: 61–73. doi: 10.1177/030006059502300108.
15.
Garnier R, Guerault E, Muzard D, Azoyan P, Chaumet-Rif faud AE, Efthymiou ML. Acute zolpidem poisoning--analysis of 344 cases. J Toxicol Clin Toxicol 1994; 32: 391–404. doi: 10.3109/15563659409011040.
16.
Gunja N. The clinical and forensic toxicology of Z-drugs. J Med Toxicol 2013; 9: 155–162. doi: 10.1007/s13181-013-0292-0.
17.
Hoque R, Chesson AL Jr. Zolpidem-induced sleepwalk ing, sleep related eating disorder, and sleep-driving: fluo rine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem. J Clin Sleep Med. 2009; 5: 471–476.
18.
Hwang TJ, Ni HC, Chen HC, Lin YT, Liao SC. Risk predictors for hypnosedative-related complex sleep behaviors: a retro spective, cross-sectional pilot study. J Clin Psychiatry 2010; 71: 1331–1335. doi: 10.4088/JCP.09m05083bro.
19.
Inagaki T, Miyaoka T, Tsuji S, Inami Y, Nishida A, Horiguchi J. Adverse reactions to zolpidem: case reports and a review of the literature. Prim Care Companion J Clin Psychiatry 2010; 12: PCC.09r00849. doi: 10.4088/PCC.09r00849bro.
20.
Inami K, Miyaoka T, Horiguchi J. Visual hallucination and amnesia after SSRI and zolpidem taking. Clinical Psychiatry 2004; 46: 985–987.
21.
Kane SP. (2019) Zolpidem Tartrate, ClinCalc DrugStats Da tabase, Version 20.0 [online]. Available at: https://clincalc. com/DrugStats/Drugs/ZolpidemTartrate (last accessed on 14.02.2020).
22.
Katz SE. Possible paroxetine-zolpidem interaction. Am J Psychiatry 1995; 152: 1689. doi: 10.1176/ajp.152.11.1689a.
23.
Kito S, Koga Y. Visual hallucinations and amnesia associated with zolpidem triggered by fluvoxamine: a possible inte raction. Int Psychogeriatr 2006; 18: 749–751. doi: 10.1017/ S1041610206214418.
24.
Leufkens TR, Lund JS, Vermeeren A. Highway driving per formance and cognitive functioning the morning after bed time and middle-of-the-night use of gaboxadol, zopiclone and zolpidem. J Sleep Res 2009; 18: 387–396. doi: 10.1111/j. 1365-2869.2009.00746.x.
25.
Mendelson WB. Sleepwalking associated with zolpidem. J Clin Psychopharmacol 1994; 14:150. doi: 10.1097/00004714- 199404000-00014.
26.
Paradis CM, Siegel LA, Kleinman SB. Two cases of zolpidem- -associated homicide. Prim Care Companion CNS Disord 2012; 14: PCC.12br01363. doi: 10.4088/PCC.12br01363.
27.
Pérez-Díaz H, Iranzo A, Santamaría J. Conductas complejas durante el sueño inducidas por zolpidem [Zolpidem-induced sleep-related behavioural disorders]. Neurologia 2010; 25: 491– 497.
28.
Poceta JS. Zolpidem ingestion, automatisms, and sleep dri ving: a clinical and legal case series. J Clin Sleep Med 2011; 7: 632–638. doi: 10.5664/jcsm.1468.
29.
Pressman MR. Factors that predispose, prime and preci pitate NREM parasomnias in adults: clinical and forensic implications. Sleep Med Rev 2007; 11:5–33. doi: 10.1016/j. smrv.2006.06.003.
30.
Pressman MR. Sleep driving: sleepwalking variant or misuse of z-drugs? Sleep Med Rev 2011; 15: 285–292. doi: 10.1016/j. smrv.2010.12.004.
31.
Ram D, Eiman N, Gowdappa B. Multimodal Hallucination (Audio-visual, Kinaesthetic and Scenic) Associated with the Use of Zolpidem. Clin Psychopharmacol Neurosci 2015; 13: 215–217. doi: 10.9758/cpn.2015.13.2.215.
32.
Salvà P, Costa J. Clinical pharmacokinetics and pharma codynamics of zolpidem. Therapeutic implications. Clin Pharmacokinet 1995; 29: 142–153. doi: 10.2165/00003088- 19952903000002.
33.
Sanofi-Aventis. (2014) https://www.ambien.com/ [online] Available at: http://products.sanofi.us/ambien/Ambien.pdf (last accessed on 14.02.2020).
34.
Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017; 13(2): 307–349. doi: 10.5664/jcsm.6470.
35.
Sattar SP, Ramaswamy S, Bhatia SC, Petty F. Somnambu lism due to probable interaction of valproic acid and zolpi dem. Ann Pharmacother 2003; 37: 1429–1433. doi: 10.1345/ aph.1C500.
36.
Schenck CH, Boyd JL, Mahowald MW. A parasomnia over lap disorder involving sleepwalking, sleep terrors, and REM sleep behavior disorder in 33 polysomnographical ly confirmed cases. Sleep 1997; 20: 972–981. doi: 10.1093/ sleep/20.11.972.
37.
Toner LC, Tsambiras BM, Catalano G, Catalano MC, Cooper DS. Central nervous system side effects associated with zol pidem treatment. Clin Neuropharmacol 2000; 23: 54–58. doi: 10.1097/00002826-200001000-00011.
38.
Tsai MJ, Huang YB, Wu PC. A novel clinical pattern of visual hallucination after zolpidem use. J Toxicol Clin Toxicol 2003; 41: 869–872. doi: 10.1081/clt-120025354
39.
Tsai MJ, Tsai YH, Huang YB. Compulsive activity and antero grade amnesia after zolpidem use. Clin Toxicol (Phila) 2007; 45:179–181. doi:10.1080/15563650600956741.
40.
Tsai JH, Yang P, Chen CC et al. Zolpidem-induced amnesia and somnambulism: rare occurrences?. Eur Neuropsychophar macol 2009; 19: 74–76. doi: 10.1016/j.euroneuro.2008.08.007.
41.
Wu-Chou, A.I. Shen, W.W. Complex behaviors related to Zolpidem: an analysis of published clinical cases from Ta iwan. J Exp Clin Med. 2012; 4: 113–118. doi: 10.1016/j.jecm. 2012.02.004.
